Summary & Overview
HCPCS J0221: Alglucosidase alfa (Lumizyme) Injection, 10 mg
HCPCS Level II code J0221 specifies a 10 mg unit of alglucosidase alfa (Lumizyme), an enzyme replacement therapy administered by injection or infusion for Pompe disease. This biologic drug code is nationally relevant due to high per-dose cost, specialized administration needs, and implications for coverage policies and care coordination for rare disease patients.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and typical sites of care, coverage and prior authorization practices among major payers, and billing benchmarks where available. The publication addresses common billing considerations for a high-cost infused biologic, including unit-based coding and implications for service lines that manage infusion therapies.
The report highlights what providers and administrators need to know about reimbursement framing, payer-specific coverage patterns, and operational considerations for delivering alglucosidase alfa. Benchmarks, policy updates, and coding notes are summarized to support administrative planning and claims submission accuracy. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0221 describes an injection of alglucosidase alfa (Lumizyme), 10 mg. This code represents the drug administration of an enzyme replacement therapy used in the treatment of Pompe disease and related glycogen storage disorders.
Service type: Drug administration (intravenous infusion or injection)
Typical site of service: Hospital outpatient department or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with confirmed Pompe disease (acid alpha-glucosidase deficiency) presents for scheduled enzyme replacement therapy with alglucosidase alfa (J0221, Lumizyme). Typical patients are adults or pediatrics with progressive proximal muscle weakness, respiratory insufficiency, and elevated creatine kinase; many have a documented diagnosis such as late-onset Pompe disease. The clinical workflow: pre-infusion nursing assessment (vital signs, allergy review, recent labs), verification of medication order and dose, reconstitution and verification of Lumizyme 10 mg vial(s) by pharmacy, establishment of intravenous access in an infusion suite or hospital outpatient infusion center, administration of infusion per prescribing information with infusion rate escalation and monitoring for infusion-associated reactions, and post-infusion observation for delayed hypersensitivity. Documentation includes medication lot and vial numbers, infusion start/stop times, pre/post vitals, any adverse reactions and management, and the applicable HCPCS code J0221 billed per 10 mg unit. Typical site of service is an outpatient infusion center, hospital outpatient department, or skilled nursing facility when clinically indicated. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|